A Study to Compare the Efficacy and Safety of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes (ACS) udergoing Percutaneous Coronary Interventions (PCI)

Trial Profile

A Study to Compare the Efficacy and Safety of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes (ACS) udergoing Percutaneous Coronary Interventions (PCI)

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Prasugrel (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PROMETHEUS
  • Most Recent Events

    • 01 Nov 2016 Results (n=19913) assessing prevalence of prasugrel use and associations between type of acute coronary syndrome and 1-year clinical outcomes, published in the Journal of the American College of Cardiology.
    • 01 Nov 2016 Results of a cohort of patients with anemia (n=3843) published in the Journal of the American College of Cardiology
    • 24 Feb 2016 Interim results (90-day efficacy and safety) published in the Society for Cardiovascular Angiography and Interventions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top